Drug Profile
Research programme: CD26 antigen antagonists - Nuada Pharmaceuticals
Alternative Names: Dipeptidyl peptidase IV anatagonists - Nuda Pharmaceuticals; DPP-IV antagonists - Nuda Pharmaceuticals; FF1Latest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator Nuada Pharmaceuticals
- Developer Nuada Pharmaceuticals (CEASED)
- Class Antihyperglycaemics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Mar 2004 Nuada Pharmaceuticals is seeking a collaborative partner for the programme (http://www.nuadapharma.com)
- 31 Mar 2004 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)